Trimodality Therapy for Muscle-Invasive Bladder Cancer: Concurrent Chemotherapy is Not Enough.
暂无分享,去创建一个
[1] W. Mackillop,et al. Estimating the optimal perioperative chemotherapy utilization rate for muscle‐invasive bladder cancer , 2019, Cancer medicine.
[2] A. Zlotta,et al. Systematic review and meta-analysis on trimodal therapy versus radical cystectomy for muscle-invasive bladder cancer: Does the current quality of evidence justify definitive conclusions? , 2019, PloS one.
[3] R. Bristow,et al. Neoadjuvant Chemotherapy Before Bladder‐Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle‐Invasive Bladder Cancer , 2019, Clinical genitourinary cancer.
[4] G. Pond,et al. Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle‐Invasive Bladder Cancer , 2019, Clinical genitourinary cancer.
[5] W. Mackillop,et al. Concurrent chemoradiotherapy for bladder cancer: Practice patterns and outcomes in the general population. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[6] W. Mackillop,et al. Perioperative chemotherapy for bladder cancer in the general population: Are practice patterns finally changing? , 2017, Urologic oncology.
[7] A. Niemierko,et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. , 2017, European urology.
[8] J. Chin,et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. , 2004, The Journal of urology.